Lichen Sclerosus
A chronic inflammatory skin condition predominantly affecting the anogenital region, causing white, atrophic patches with intense pruritus. Most common in postmenopausal women. Associated with ~4–5% risk of vulval SCC. First-line treatment is ultrapotent topical corticosteroids (clobetasol propionate 0.05%).
Key Facts
Predominantly anogenital: vulval (most common), penile (BXO — balanitis xerotica obliterans) Postmenopausal women: peak incidence; also occurs prepubertally White, atrophic patches: porcelain-white, crinkled 'cigarette paper' skin; figure-of-eight pattern around vulva and anus SCC risk: ~4–5% lifetime risk of vulval SCC in lichen sclerosus Clobetasol propionate 0.05%: first-line — OD for 4 weeks, alternate days for 4 weeks, twice weekly for 4 weeks (step-down) Autoimmune association: thyroid disease, vitiligo, pernicious anaemia BXO in males: may cause phimosis, meatal stenosis — may require circumcision Long-term follow-up: required due to malignant potential
Overview
Key Facts
Lichen sclerosus (LS) is a chronic, inflammatory skin disease with a predilection for the anogenital region. It is important because of its significant impact on quality of life and its association with vulval and penile SCC.
Epidemiology
- Estimated prevalence: 1 in 300–1,000 women
- Bimodal age distribution: prepubertal girls and postmenopausal women
- F:M ~10:1
- Males (BXO): any age, including children — may present with phimosis
Aetiology
- Autoimmune: strong association with other autoimmune conditions (thyroid disease ~30%, vitiligo, pernicious anaemia)
- Genetic predisposition: HLA-DQ7 association
- Hormonal: oestrogen deficiency may contribute (postmenopausal predominance)
- Chronic irritation/trauma: Koebner phenomenon reported
- NOT sexually transmitted
Pathophysiology
- Autoimmune T-cell mediated attack on dermal-epidermal junction
- Homogenisation and hyalinisation of upper dermis → sclerosis
- Epidermal atrophy with loss of rete ridges
- Progressive scarring → architectural distortion of vulva (labial fusion, clitoral burying) or phimosis in males
- Chronic inflammation → increased SCC risk
Clinical Presentation
Vulval Lichen Sclerosus
- Porcelain-white, atrophic patches affecting vulva and perianal skin
- Figure-of-eight distribution around vulva and anus
- Intense pruritus — worse at night; may cause sleep disturbance
- Skin fragility: fissuring, erosions, purpura, ecchymoses
- Progressive scarring: labial fusion, clitoral hooding/burying, introital narrowing → dyspareunia
- Secondary infection common
Penile Lichen Sclerosus (BXO)
- White patches on glans and prepuce
- Phimosis (inability to retract foreskin) — most common presentation in males
- Meatal stenosis → urinary difficulties
- Frenular scarring
Extragenital Lichen Sclerosus
- ~15–20% of patients have extragenital lesions
- White, atrophic patches on trunk, proximal limbs
- Usually asymptomatic
Red Flags
- Persistent, thickened, or warty area within LS — biopsy to exclude SCC (4–5% lifetime risk)
- Bleeding or non-healing ulcer
- Failure to respond to appropriate topical steroid treatment
- Severe architectural distortion requiring surgical assessment
Differential Diagnosis
| Diagnosis | Key Features | Investigation |
|---|---|---|
| Vulval SCC | Raised, warty, or ulcerated lesion within LS | Biopsy |
| Lichen planus (erosive) | Painful erosions, lacy white pattern, vaginal involvement | Biopsy |
| Vitiligo | Depigmentation without atrophy or sclerosis | Clinical |
| Vulvovaginal candidiasis | Discharge, erythema, satellite lesions | Swab |
| Lichen simplex chronicus | Thickened, lichenified skin from chronic scratching | Clinical, biopsy |
| Sexual abuse (children) | Bruising, fissures — LS may mimic; careful assessment needed | MDT assessment |
Diagnosis / Investigation
Bedside
- Clinical examination: often diagnostic in classic presentation; full anogenital examination
Bloods
- Autoimmune screen: thyroid function (TFTs), anti-thyroid antibodies, B12 (pernicious anaemia)
- FBC: if anaemia suspected
Biopsy
- Punch biopsy: not always needed for classic presentation but recommended if:
- Diagnostic uncertainty
- Suspected SCC (thickened, warty, or ulcerated area)
- Treatment failure
- Pigmented lesion within LS
- Histology: epidermal atrophy, loss of rete ridges, homogenisation of upper dermis, band-like lymphocytic infiltrate beneath sclerotic zone
Special Tests
- Not routinely required
- Vulvoscopy: detailed examination in specialist clinic
Management
Non-Pharmacological
- Patient education: chronic condition requiring long-term maintenance treatment
- Emollients: regular use as soap substitutes and moisturisers (aqueous cream should NOT be used as leave-on — use alternatives)
- Avoid irritants: soap, bubble bath, tight clothing
- Sexual health support: dyspareunia counselling, lubricants
Pharmacological
- Clobetasol propionate 0.05% ointment: first-line — highly effective
- Induction: OD for 4 weeks → alternate days for 4 weeks → twice weekly for 4 weeks
- Maintenance: typically 1–2 times per week long-term
- ~95% respond to appropriate topical steroid treatment
- Topical tacrolimus 0.1%: second-line if steroids contraindicated or ineffective (off-licence)
- Topical oestrogen: may help in postmenopausal women as adjunct (limited evidence)
Surgical
- Circumcision: curative for penile LS (BXO) in most cases
- Vulval surgery: for adhesions, introital stenosis, clitoral de-hooding — improves function
- Meatotomy/meatoplasty: for meatal stenosis in males
- Excision of suspicious lesions: to exclude SCC
Referral Criteria
- Dermatology/vulval clinic: diagnostic uncertainty, treatment failure, suspected malignancy
- Urology: BXO with phimosis or meatal stenosis
- Paediatric dermatology: suspected LS in children
- Safeguarding: LS in children may be misdiagnosed as abuse and vice versa — expert assessment required
Prognosis
- Chronic relapsing condition — lifelong maintenance treatment usually required
- ~95% respond well to topical clobetasol propionate
- Vulval SCC risk: ~4–5% lifetime in women with LS — requires long-term monitoring
- Penile SCC risk: lower but present; circumcision significantly reduces risk
- Prepubertal LS: may improve or resolve at puberty in some girls
- Scarring is irreversible — early, adequate treatment prevents architectural distortion
- Quality of life: significantly impacted by pruritus, dyspareunia, and psychological effects
Other Relevant Information
Lichen Sclerosus vs Lichen Planus (Vulval)
| Feature | Lichen Sclerosus | Lichen Planus |
|---|---|---|
| Primary symptom | Pruritus | Pain |
| Appearance | White, atrophic, sclerotic | Erosive, violaceous |
| Vaginal involvement | No (vulval only) | Yes (may cause adhesions) |
| Malignant potential | ~4–5% SCC | ~2–3% SCC |
| Treatment | Clobetasol propionate | Clobetasol propionate |
| Scarring pattern | Labial fusion, clitoral burying | Vaginal adhesions |
Clobetasol Step-Down Regimen
| Phase | Duration | Frequency |
|---|---|---|
| Induction | 4 weeks | Once daily |
| Step-down 1 | 4 weeks | Alternate days |
| Step-down 2 | 4 weeks | Twice weekly |
| Maintenance | Long-term | 1–2 times/week |